PHILADELPHIA, May 19, 2023 (WORLD NEWSWIRE) — Scout Bio, a biotechnology business establishing healing proteins and one-time AAV gene treatments for significant persistent animal health conditions, today revealed that executive officers Mark Heffernan and Anne Traas, together with co-founder Matthew Wilson, will provide at the 26th yearly American Society of Gene and Cell Therapy (ASGCT) Summit in Los Angeles, California on May 20, 2023.
-
Scout Bio Chief Executive Officer Mark Heffernan, Ph.D., will provide an Overview of Animal Health Industry Similarities and Differences from Human Health. Saturday, May 20, at 8:11 a.m. PST.
-
Scout Bio Chief Development Officer Anne Traas, DVM MS DACT, will go over Disease Indications in Animal Health: One Medicine Approach to Gene Therapy. Saturday, May 20, at 9:55 a.m. PST.
-
Scout Bio co-founder Matt Wilson will information CMC Strategy – Decreasing Cost of Goods for Animal Health Market. Saturday, May 20, at 10:20 a.m. PST.
All 3 will participate in a panel conversation from 11am-12pm on Saturday.
About ASGCT
The American Society of Gene & Cell Therapy is the main expert subscription organization for gene and cell treatment. The Society’s members are researchers, doctors, client supporters, and other specialists. Members operate in a wide variety of settings consisting of universities, medical facilities, federal government firms, structures, and biotechnology and pharmaceutical business.
The objective of ASGCT is to advance understanding, awareness, and education resulting in the discovery and scientific application of hereditary and cellular treatments to ease human illness. ASGCT’s tactical vision is to be a driver for combining researchers, doctors, client supporters, and other stakeholders to change the practice of medication by integrating making use of hereditary and cellular treatments to manage and treat human illness.
About Scout Bio
Scout Bio is a biotechnology business reinventing animal medication by providing a pipeline of one-time gene treatments and monoclonal antibodies for significant persistent animal health conditions. Scout Bio’s treatments are developed to cause long-lasting expression of healing proteins in animal clients utilizing AAV vector innovation. Scout Bio has a research study and advancement cooperation with the University of Pennsylvania’s Gene Therapy Program, a leader in the field of hereditary medication research study. Scout Bio is a personal business headquartered in Philadelphia, Pennsylvania. For more details, see www.scoutbio.co.
For additional details, please contact:
Fran Gaconnier
Scout Bio
214.417.4142
[email protected]
